Sienna Biopharmaceuticals, a clinical-stage biotech developing topical therapies for dermatological conditions, raised $65 million by offering 4.3 million shares at $15, the midpoint of the range of $14 to $16. Insiders had indicated an interest in buying up to $25 million on the IPO, representing 38.5% of the deal. Sienna Biopharmaceuticals plans to list on the Nasdaq under the symbol SNNA. J.P. Morgan and Cowen & Company acted as lead managers on the deal.
